These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
7. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451 [TBL] [Abstract][Full Text] [Related]
8. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer]. García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844 [TBL] [Abstract][Full Text] [Related]
10. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]
14. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265 [TBL] [Abstract][Full Text] [Related]
15. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589 [TBL] [Abstract][Full Text] [Related]
16. Improving Diagnosis of Primary Prostate Cancer With Combined Jena A; Taneja R; Taneja S; Singh A; Kumar V; Agarwal A; Subramanian N AJR Am J Roentgenol; 2018 Dec; 211(6):1246-1253. PubMed ID: 30300002 [TBL] [Abstract][Full Text] [Related]
17. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
18. Potential Impact of Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978 [TBL] [Abstract][Full Text] [Related]
19. Role of Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596 [TBL] [Abstract][Full Text] [Related]
20. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Lin CY; Lee MT; Lin CL; Kao CH Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]